Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Laboratorios Farmaceuticos Rovi, S.A.

Ratings ESG MSCI

Ratings ESG MSCI - Laboratorios Farmaceuticos Rovi, S.A.

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • With an enterprise value anticipated at 3.89 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Most analysts recommend that the stock should be sold or reduced.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.33B
BBB
1,043B
A
618B
BBB
481B
AAA
-
351B
AA
338B
AA
269B
AAA
244B
A
220B
BBB
182B
AA
Average 375B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. 0ILL Stock
  5. Ratings Laboratorios Farmaceuticos Rovi, S.A.